Monte Rosa Therapeutics, Inc. GLUE Total debt

Total debt at other companies

Bristol-Myers SquibbBMY

$43.33B-12.3%

Nurix Therapeutics, Inc.NRIX

$58.14M+12.0%

ArvinasARVN

$8.6M-19.6%

Kymera TherapeuticsKYMR

$80.14M-8.5%

Vor BiopharmaVOR

$2.94M-90.5%

BiohavenBHVN

$286.18M+706%

FAQ

What is Monte Rosa Therapeutics, Inc.'s total debt?

Monte Rosa Therapeutics, Inc. (GLUE) reported total debt of $37.99M in Q2 2026.

How has Monte Rosa Therapeutics, Inc.'s total debt changed year-over-year?

Monte Rosa Therapeutics, Inc.'s total debt decreased by 7.6% year-over-year, from $41.13M to $37.99M.

What is the long-term trend for Monte Rosa Therapeutics, Inc.'s total debt?

Over 4 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s total debt has grown at a 51.7% compound annual growth rate (CAGR), from $7.4M to $39.19M.

What does total debt mean?

Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.